Acutaas Chemicals LimitedQ1 FY27 Results & Financial Update
Acutaas Chemicals Limited: Q1 FY27 consolidated results and company financials – revenue ₹329.67 Cr, PAT ₹74.99 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Acutaas Chemicals price & chart
Market priceLoading…
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Acutaas Chemicals Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Acutaas Chemicals Limited reported robust operating performance for the first quarter ended June 30, 2026, delivering consolidated revenue from operations of INR 3,297 million (INR 329.67 crore), representing a year-on-year growth of 59.1% compared to INR 2,072 million in Q1 FY26, as per the company's official press release.
The significant top-line expansion was driven by strong momentum across the advance intermediates and custom synthesis (CDMO) businesses, alongside solid growth in the Baba Fine Chemicals (BFC) division, which offset softer performance in commodity chemical lines.
Gross profitability for the quarter rose 73.0% year-on-year to INR 1,909 million from INR 1,103 million, leading to a gross margin expansion of 466 basis points to 57.9% compared to 53.2% in the corresponding quarter of the previous fiscal year, supported by favorable product mix and improved operational efficiencies.
Consolidated EBITDA surged 122.1% year-on-year to INR 1,131 million from INR 509 million in Q1 FY26, while the EBITDA margin expanded sharply by 970 basis points to 34.3% from 24.6%, reflecting strong operating leverage and cost optimization across manufacturing units.
Profit after tax (PAT) for the quarter grew 70.4% year-on-year to INR 750 million (reported statutory profit for the period stood at INR 74.99 crore) compared to INR 440 million in Q1 FY26. The PAT margin stood at 22.7%, up 151 basis points year-on-year, though bottom-line growth was partially tempered by lower other income of INR 18 million compared to INR 159 million in Q1 FY26.
On a sequential basis, revenue from operations declined 23.8% from INR 4,328 million in Q4 FY26, and PAT decreased 44.2% from INR 1,343 million, reflecting typical quarterly project delivery cycles and fluctuations in other income.
During the quarter, the company's subsidiary, Acutaas Chemicals Electrolytes Private Limited (ACEPL), completed a preferential equity share issue on a partly paid-up basis to A.R.Z Pharma Ltd., diluting the parent company's holding from 100% to 90% as of May 19, 2026, while retaining management control.
01 · Business model
What does Acutaas Chemicals do?
Acutaas Chemicals Limited (formerly known as Ami Organics Limited) is a specialized global chemical manufacturer focusing on research-driven development and production across multiple high-end verticals, including advanced pharmaceutical intermediates, custom synthesis and manufacturing (CDMO), and specialty chemicals.
The company's product portfolio serves regulated and generic API manufacturers, agrochemicals, fine chemicals, personal care, and emerging technology sectors such as battery electrolytes, advanced semiconductor materials, and next-generation electronic applications.
Operating through its registered office and manufacturing infrastructure in Sachin GIDC, Surat, Gujarat, Acutaas integrates specialized subsidiaries and partnership firms—such as Acutaas Chemicals Electrolytes Private Limited and Baba Fine Chemicals—to broaden its manufacturing and technology footprint.
The business model leverages strong process chemistry capabilities, custom development contracts, and expanding applications in high-value electronic and energy storage markets to support diversified revenue streams.
02 · Historical context
What shaped the business before this quarter
Previously known as Ami Organics Limited, the company transitioned its corporate identity to Acutaas Chemicals Limited to reflect its broader technological scope and specialized chemistry apex.
03 · Financial snapshot
Current-quarter financial snapshot
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹329.67 Cr |
| Total income | ₹331.48 Cr |
| Profit before tax | ₹103.91 Cr |
| Profit after tax | ₹74.99 Cr |
| EPS | ₹9.04 |
Financial interpretation
What the reported numbers mean
Profit after tax represented 22.7% of reported quarterly operating revenue. This is a calculated net-profit-to-sales ratio, not a company-reported operating margin. It measures the outcome after expenses and tax; it does not, by itself, establish how margins changed versus another period.
Profit before tax was equivalent to 31.5% of quarterly operating revenue. The distinction between pre-tax and post-tax profit matters when interpreting earnings; neither ratio identifies an underlying cost driver without a properly matched comparative period.
Total income exceeded operating revenue by ₹1.80 crore. This is the disclosed difference between the two lines, not incremental sales. The distinction matters when assessing how much of the quarter’s reported income came from the operating top line.
Ratios above are calculated from the reported quarterly figures. They are analytical descriptions, not company-reported margin guidance or an investment recommendation.
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
Advance intermediates revenue grew 76.5% year-on-year to INR 2,927 million in Q1 FY27 from INR 1,658 million in Q1 FY26, driven by sustained contract manufacturing momentum and robust demand in regulated pharmaceutical markets.
Specialty chemicals revenue was INR 370 million in Q1 FY27 compared to INR 414 million in Q1 FY26 (-10.6% YoY), reflecting strong growth in the Baba Fine Chemicals (BFC) business offset by subdued performance in commodity-linked lines.
What drove margins
Gross margins improved to 57.9% in Q1 FY27 from 53.2% in Q1 FY26, an expansion of 466 basis points, driven by an enriched product mix favoring higher-value advanced intermediates and better raw material cost realization.
EBITDA margin expanded by 970 basis points year-on-year to 34.3% from 24.6%, benefiting from operating leverage as fixed overheads were distributed over a substantially larger top-line base.
05 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
The company continues to operate in a single primary business segment: custom synthesis and manufacturing of specialty chemicals with applications in pharmaceutical APIs and others, in accordance with Ind AS 108.
06 · Strategy & new businesses
How the company is trying to change its growth mix
During the quarter ended June 30, 2026, Acutaas Chemicals Electrolytes Private Limited issued partly paid-up equity shares to A.R.Z Pharma Ltd., diluting Acutaas Chemicals' stake from 100% to 90% effective May 19, 2026, while maintaining effective control.
The company continues to advance its portfolio expansion into high-value specialty chemicals tailored for emerging applications, including battery electrolytes, advanced semiconductor materials, and electronic chemicals.
07 · Reported developments
What changed operationally
The company was certified as a Great Place to Work during the quarter, validating its organizational culture and employee engagement.
Acutaas received the Responsible Care certification from the Indian Chemical Council, reflecting adherence to international standards for safety, health, and environmental management.
08 · Pressure points & risks
What is not going smoothly
The Central Goods & Service Tax and Central Excise (CGST & CE) Anti-Evasion Department initiated inspection and search proceedings at the company's registered office and Surat manufacturing facility on June 22, 2026, which concluded on June 23, 2026. Management reported no expected material impact on financial position, operations, or cash flows based on available information.
09 · Items worth noticing
The line items that can distort a quick read
Other income declined to INR 18.01 million (INR 1.80 crore) in Q1 FY27 from INR 159.38 million in Q1 FY26, creating a headlock on net profit growth despite strong operating performance.
10 · Management guidance & targets
What management is targeting from here
Management stated confidence in delivering 25% revenue growth for the full fiscal year FY27 while maintaining stable operating margins.
11 · Beyond the numbers
What changed beyond the numbers
Reported update
Workplace and Environmental Recognition
Acutaas secured both the 'Great Place to Work' certification and the Indian Chemical Council's 'Responsible Care' certification during Q1 FY27, reinforcing its commitment to human capital and sustainable manufacturing standards.
12 · Key Q&A
The quarter, answered directly
What does Acutaas Chemicals do?
Acutaas Chemicals Limited (formerly known as Ami Organics Limited) is a specialized global chemical manufacturer focusing on research-driven development and production across multiple high-end verticals, including advanced pharmaceutical intermediates, custom synthesis and manufacturing (CDMO), and specialty chemicals.
What is the clearest takeaway from Q1 FY27?
Acutaas Chemicals Limited reported robust operating performance for the first quarter ended June 30, 2026, delivering consolidated revenue from operations of INR 3,297 million (INR 329.67 crore), representing a year-on-year growth of 59.1% compared to INR 2,072 million in Q1 FY26, as per the company's official press release.
What drove revenue or demand?
Advance intermediates revenue grew 76.5% year-on-year to INR 2,927 million in Q1 FY27 from INR 1,658 million in Q1 FY26, driven by sustained contract manufacturing momentum and robust demand in regulated pharmaceutical markets.
What mattered most for margins or profitability?
Gross margins improved to 57.9% in Q1 FY27 from 53.2% in Q1 FY26, an expansion of 466 basis points, driven by an enriched product mix favoring higher-value advanced intermediates and better raw material cost realization.
What changed operationally beyond the headline numbers?
During the quarter ended June 30, 2026, Acutaas Chemicals Electrolytes Private Limited issued partly paid-up equity shares to A.R.Z Pharma Ltd., diluting Acutaas Chemicals' stake from 100% to 90% effective May 19, 2026, while maintaining effective control.
What is management guiding or targeting from here?
Management stated confidence in delivering 25% revenue growth for the full fiscal year FY27 while maintaining stable operating margins.
13 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
14 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Full-Year Revenue Target: Monitor actual revenue progression against management's stated aspiration of 25% annual revenue growth for FY27.
- 02
Regulatory Proceedings Resolution: Track any formal disclosures or final determinations regarding the CGST & CE anti-Evasion search proceedings conducted in June 2026.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.